(+035) 527-1710-70
New pharmaceutical development opens up entry into blockbuster markets
SALT LAKE CITY and TORONTO, July 29, 2014 /PRNewswire/ — EastGate Acquisitions
Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery
innovations in the development of improved novel formulations and alternative dosage forms of
existing biologically active molecules announces expansion of its pharmaceutical development
implementing its sub-micron platform technology. The company’s new development
direction includes large molecule drugs that will address indications in diabetes and the overall
metabolic syndrome.
The company’s sub-micron technology allows for development of harmonized formulations
and better absorption. To date, the company has demonstrated initial proven success of the
technology with Lorazepam in animals. In its application for specific pharmaceutical molecules
the company has been able to achieve positive results with drugs that are currently injected. The
company continues the development of its transmucosal Lorazepam Spray for the treatment of
acute seizures.
After much exploratory work the company has expanded its research to include the delivery
of large molecules, such as insulin and other peptides through an intraoral route. The delivery
methods considered for intraoral insulin formulation includes liquid, semi-solid and other types
of sub-micron compositions; all of which are delivered in the mouth for intraoral absorption.
Initial testing of some insulin formulations for glucose control have been conducted with
successful results. Future plans for next steps are currently being designed.
Intraoral insulin opens up the opportunity to enter into and play a role in the enormous and fast-
growing diabetes and metabolic syndrome treatment markets. There are currently 347 million
diabetes patients throughout the world and 36 million in the United States alone. This diabetes
product platform will be an avenue to be used by the critical masses.
“We are planning to finalize the details of the development, clinical and regulatory plan for our
intraoral insulin platform soon,” says Anna Gluskin, EastGate’s CEO. “This diabetes-focused
development will achieve opportunities on a number of fronts—it continues to validate our sub-
micron technology; opens up opportunities to enter large blockbuster markets servicing the
growing chronic diabetes patient population and provides shareholders with an exciting and
value-added exit strategy,” states Gluskin.
About EastGate Acquisitions Corporation
EastGate Acquisitions Corporation with locations in Salt Lake City, Utah and Toronto, Canada,
is a pharmaceutical company aimed at utilizing drug delivery innovations for developing of
improved novel formulations and alternative dosage forms of existing biologically active
molecules. The Company’s model is based on a two-tier business approach that includes
development of novel pharmaceutical products and innovative dietary supplements. Both
pharmaceutical products and natural supplements are developed using highly effective
contemporary technologies and demonstrated already proven usefulness in improvement
of bioavailability and biological action of incorporated molecules. The Company’s product
candidates address various pharmaceutical markets, including neurological disorders, such as
epilepsy and panic attacks, infectious diseases and diabetes. Our natural dietary supplements,
also an integral part of our R&D program, include compositions for glucose regulations,
urinary tract health improvement, enhanced vitamin delivery and skin conditions. EastGate is
working to expand its current product portfolio through targeted investments in pharmaceutical
research and development. We are working closely with clinicians and patient advocate
groups worldwide to identify existing health issues where EastGate’s approach will be most
beneficial for patient care. For more information, please visit the company’s website at
www.EastGatePharmaceuticals.com.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference
in this news release constitute “forward-looking information” or “forward-looking statements”
within the meaning of certain securities laws, including the provisions for “safe harbour”
under the United States Private Securities Litigation Reform Act of 1995 and are based on
expectations, estimates and projections as of the date of this news release.
The
words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “esti
mates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”,
“outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or
variations of or similar such words and phrases or statements that certain actions, events or
results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will
occur” or “will be achieved” and similar expressions identify forward-looking statements.
Forward-looking statements are necessarily based upon a number of estimates and assumptions
that, while considered reasonable by EastGate as of the date of such statements, are inherently
subject to significant business, economic and competitive risks, uncertainties and contingencies.
The risks, estimates, models and assumptions contained or incorporated by reference in this
news release, include those identified from time to time in the reports filed by EastGate with the
Securities and Exchange Commission, which should be considered together with any forward-
looking statement. EastGate undertakes no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events or otherwise.
CONTACT: Rose Perri 1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Text: ESAQ to 87804